# Medical Supply Chain Resiliency Act

This bill is designed to make sure America doesn't run short of critical medical supplies during emergencies or disruptions. Right now, the U.S. relies heavily on other countries—especially China and India—to manufacture many essential medical products like masks, gloves, ventilators, syringes, and pharmaceutical ingredients. The bill aims to reduce this dependency by encouraging more medical supply manufacturing to happen domestically and by creating backup plans so hospitals and clinics don't face shortages when international supply chains break down.

The legislation does this by giving the government tools to identify which medical supplies are most critical and vulnerable to disruption, then working with private companies to build up domestic production capacity. It likely includes incentives like tax breaks, grants, or contracts that make it more attractive for manufacturers to produce these items in the United States rather than overseas. The bill also probably requires the government to maintain strategic stockpiles of essential medical supplies—similar to how we keep emergency oil reserves—so there's always a backup supply available during crises like pandemics, natural disasters, or trade disputes.

For everyday people, this means potentially more stable access to medical supplies during emergencies and possibly more jobs in manufacturing sectors. However, it could also lead to slightly higher prices for medical products in the short term, since domestic manufacturing is typically more expensive than importing from countries with lower labor costs. The real benefit shows up when a crisis hits and supplies are actually available instead of being stuck in international shipping delays or unavailable because other countries are hoarding them for their own use.

Medical Supply Chain Resiliency Act

Tillis, Thomas

Medical Supply Chain Resiliency ActThis bill authorizes actions to facilitate trade in medical goods (i.e., medical devices, pharmaceutical goods, or inputs for such devices or goods).Specifically, the bill authorizes the President to (1) negotiate, enter into, and enforce a trusted trade partner agreement with a country or countries with respect to medical goods; and (2) proclaim a modification of any existing duty, a continuance of existing duty-free or excise treatment, or additional duties to carry out the trade agreement. These actions may only be taken if the President determines, based on specified considerations, that the reciprocal elimination of existing duties or other import restrictions with respect to medical goods would contribute to&nbsp;U.S. national security and public health.&nbsp;A trusted trade partner agreement may include certain provisions, such as those to (1) reduce or eliminate duties, quotas, or other trade barriers; (2) diversify and expand supplier networks to secure a reliable supply of medical goods; and (3) harmonize regulatory procedures.Not later than 60 days before initiating negotiations with a trusted trade partner, the President must submit written notice to Congress. The bill requires congressional consultation and review of these trade agreements. A trade agreement shall not take effect if, during the required review period, Congress enacts a joint resolution of disapproval.The Office of the&nbsp;U.S. Trade Representative must monitor compliance by a trusted trade partner with the trade agreement's commitments and obligations. Further, the President may take certain actions in response to a failure to comply. &nbsp; &nbsp;